Alpha 2.0
Login Register
» Authors » D Warr

D Warr

Explore the profile of D Warr including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 50
Citations 1429
Followers 0
Related Specialties
Oncology
Critical Care
General Medicine
Top 10 Co-Authors
J Latreille
D Osoba
J Pater
L Kaizer
B Zee
J Rusthoven
B Findlay
F Laberge
S Fine
M N Levine
Published In
J Clin Oncol
Support Care Cancer
Ann Oncol
N Z Nurs J
J Natl Cancer Inst
Affiliations
Soon will be listed here.
Recent Articles
1.
Cannabinoids as antiemetics: everything that's old is new again
Warr D, Hesketh P
Ann Oncol . 2020 Aug; 31(11):1425-1426. PMID: 32860877
No abstract available.
2.
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla R, Bruera E, et al.
Ann Oncol . 2016 Sep; 27(suppl 5):v119-v133. PMID: 27664248
No abstract available.
3.
[Not Available]
Warr D
Nurs Stand . 2016 May; 6(27):4. PMID: 27236932
Any new publication brings with it a source of reference, a revitalisation and an opportunity for change. Therefore, it is invigorating for accident and emergency nurses to have this supplement...
4.
A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer
Vardy J, Pond G, Dodd A, Warr D, Seruga B, Clemons M, et al.
Breast Cancer Res Treat . 2012 Sep; 136(1):143-51. PMID: 22956006
Uncertainty remains about the optimal anti-emetic regimen for control of delayed nausea and vomiting after adjuvant chemotherapy for breast cancer. Many patients receive dexamethasone but complain of insomnia, anxiety/agitation, and...
5.
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
Roila F, Herrstedt J, Aapro M, Gralla R, Einhorn L, Ballatori E, et al.
Ann Oncol . 2010 Jun; 21 Suppl 5:v232-43. PMID: 20555089
No abstract available.
6.
Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study
Dranitsaris G, Leung P, Warr D
Support Care Cancer . 2002 Jan; 9(8):611-8. PMID: 11762972
There is a considerable gap between obtaining results in randomized trials and implementing them into practice. This is particularly relevant with the high-cost 5HT3 antiemetics, which include ondansetron, dolasetron and...
7.
A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer
Cunningham A, Edmonds C, Jenkins G, Pollack H, Lockwood G, Warr D
Psychooncology . 1999 Jan; 7(6):508-17. PMID: 9885092
In order to test the effect of a psychological intervention on survival from cancer, 66 women with metastatic breast cancer, all receiving standard medical care, were randomly assigned into two...
8.
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada...
Levine M, Bramwell V, Pritchard K, Norris B, Shepherd L, Findlay B, et al.
J Clin Oncol . 1998 Aug; 16(8):2651-8. PMID: 9704715
Purpose: To determine the relative efficacy of an intensive cyclophosphamide, epirubicin, and fluorouracil (CEF) adjuvant chemotherapy regimen compared with cyclophosphamide, methotrexate, and fluorouracil (CMF) in node-positive breast cancer. Patients And...
9.
Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration
Gandara D, Roila F, Warr D, Edelman M, Perez E, Gralla R
Support Care Cancer . 1998 Jun; 6(3):237-43. PMID: 9629876
Selective antagonists to the Type 3 serotonin receptor (5HT3) in combination with corticosteroids are now considered the standard of care for the prevention of emesis from moderately to highly emetogenic...
10.
Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen
Warner E, Hedley D, Andrulis I, Myers R, Trudeau M, Warr D, et al.
Clin Cancer Res . 1998 Jun; 4(6):1451-7. PMID: 9626462
The purpose of this study is to evaluate whether metastatic breast cancer that has progressed on an anthracycline-containing drug regimen will subsequently respond to that identical regimen if dexverapamil, a...